title: YKL-40 and MMP-9 as serum markers for patients with primary central nervous system lymphoma.
abstract: OBJECTIVE
  To evaluate YKL-40 and MMP-9 proteins as tumor biomarkers in serum samples from patients with primary central nervous system lymphoma (PCNSL).
  
  
  METHODS
  In this prospective longitudinal study, serum samples from consecutive patients with histologically confirmed PCNSL were collected concurrently with magnetic resonance imaging (MRI) scans at multiple time points and were analyzed for levels of YKL-40 and MMP-9 by enzyme-linked immunosorbent assay. Marker levels were correlated to disease status and survival.
  
  
  RESULTS
  Forty-five patients with PCNSL were accrued. Median follow-up for survivors was 25 months, and 21 (47%) died during the study. A total of 230 serum samples were collected, and 93% had corresponding MRI scans. PCNSL patients without evidence of radiographic disease (29 patients, 131 samples) had significantly lower levels of serum YKL-40 and MMP-9 than patients with active tumor (n = 34 patients, 84 samples; p = 0.03 and 0.01, respectively). There was a significant inverse correlation between survival and doubling of the YKL-40 level (hazard ratio, 1.7; p = 0.01).
  
  
  CONCLUSIONS
  In patients with PCNSL, serum levels of YKL-40 and MMP-9 are associated with radiographic disease status. Longitudinal increase in serum levels of YKL-40, but not MMP-9, predicts survival in patients with PCNSL.
authors.affiliation: Brain Tumor Center, New York, NY, USA.
authors.forename: Andreas F
authors.initials: AF
authors.lastname: Hottinger
authors.forename: Fabio M
authors.initials: FM
authors.lastname: Iwamoto
authors.forename: Sasan
authors.initials: S
authors.lastname: Karimi
authors.forename: Elyn
authors.initials: E
authors.lastname: Riedel
authors.forename: Jocelynn
authors.initials: J
authors.lastname: Dantis
authors.forename: Joseph
authors.initials: J
authors.lastname: Park
authors.forename: Katherine S
authors.initials: KS
authors.lastname: Panageas
authors.forename: Andrew B
authors.initials: AB
authors.lastname: Lassman
authors.forename: Lauren E
authors.initials: LE
authors.lastname: Abrey
authors.forename: Martin
authors.initials: M
authors.lastname: Fleisher
authors.forename: Eric C
authors.initials: EC
authors.lastname: Holland
authors.forename: Lisa M
authors.initials: LM
authors.lastname: DeAngelis
authors.forename: Adília
authors.initials: A
authors.lastname: Hormigo
mesh_terms: D054392:Adipokines; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D014408:Biomarkers, Tumor / Q000097:blood* / Q000378:metabolism; D016543:Central Nervous System Neoplasms / Q000097:blood* / Q000175:diagnosis / Q000201:enzymology; D000071451:Chitinase-3-Like Protein 1; D005260:Female; D006023:Glycoproteins / Q000097:blood*; D006801:Humans; D037102:Lectins / Q000097:blood*; D008137:Longitudinal Studies; D008228:Lymphoma, Non-Hodgkin / Q000097:blood* / Q000175:diagnosis / Q000201:enzymology; D008297:Male; D020780:Matrix Metalloproteinase 9 / Q000097:blood*; D008875:Middle Aged; D011446:Prospective Studies; D055815:Young Adult
chemical_list: D054392:Adipokines; D014408:Biomarkers, Tumor; C084533:CHI3L1 protein, human; D000071451:Chitinase-3-Like Protein 1; D006023:Glycoproteins; D037102:Lectins; D020780:Matrix Metalloproteinase 9